Pfizer pays $47.5M for Nordic rights to haemophilia drugs from Swedish Orphan

Pfizer has paid $47.5 million to reclaim full commercialisation rights to the blood clotting factors ReFacto and BeneFIX in the Nordic region from Swedish Orphan Biovitrum (Sobi), which held co-promotion rights there.